Lexicon Pharmaceuticals reported $186.03M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Akebia Therapeutics USD 220.78M 8.77M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Illumina USD 3.04B 201M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 295.08M 26.61M Sep/2026
MannKind USD 240.48M 5.24M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025